Back to Search
Start Over
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
- Publication Year :
- 2018
- Publisher :
- Elsevier Limited, 2018.
-
Abstract
- Background: The development of immune checkpoint blocker development brings new hope in older patients (OPs) because of clinical efficacy and low toxicity. Clinical indications are rising steadily, but very few data are available in the geriatric population where comorbidities, reduced functional reserve and immunosenescence may affect efficacy and tolerance. Methods: All cases of patients enrolled in immunotherapy phase I trials between January 2012 and December 2016 in the Drug Development Department (DITEP) at Gustave Roussy were retrospectively reviewed. Case–control analysis was performed in OPs (patients ≥ 70 years) matched to younger patients (YPs) (patients < 70 years) by trial and treatment dose. We compared cumulative incidence, grade and type of immune-related adverse events (IrAEs) and survival outcomes. Results: Among the 46 OPs and the 174 YPs enrolled in 14 phase I/II trials, 10 (22%) and 23 (13%) patients experienced grade III–IV IrAEs. Cumulative incidence of grade I–II IrAEs was significantly higher in OPs than YPs (p < 0.05). No significant difference was observed between the two groups for grade III–IV IrAEs (p = 0.50). Older age was not associated with lower dose intensity of treatment (p = 0.14). No significant difference was observed between OPs and YPs in median progression-free survival (hazards ratio 1.41, 95% confidence interval [CI] [0.94–2.11] p = 0.09) or median overall survival (HR 0.92, 95% CI [0.61–1.39] p = 0.77). Conclusion: Immune checkpoint blockade appears to be an acceptable treatment option for OPs in the setting of phase I trials.
- Subjects :
- 0301 basic medicine
Adult
Male
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
Case-control studies
03 medical and health sciences
0302 clinical medicine
Neoplasms
Internal medicine
medicine
Clinical Trials, Phase I as Topic/statistics & numerical data
Humans
Cumulative incidence
Young adult
Age of Onset
Aged
Retrospective Studies
Clinical Trials, Phase I as Topic
business.industry
Case-control study
Age Factors
Retrospective cohort study
Immunosenescence
Immunotherapy
Middle Aged
Immune checkpoint
030104 developmental biology
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Disease Progression
Immunotherapy/methods
young adult
Female
Age of onset
business
aged, 80 and over
Neoplasms/epidemiology
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....6de4bd6c24661e08ded6fc9bb365b0c7